Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Up – Still a Buy?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) gapped up prior to trading on Wednesday . The stock had previously closed at $24.21, but opened at $26.10. Damora Therapeutics, Inc. Common Stock shares last traded at $26.30, with a volume of 5,209 shares.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Evercore started coverage on Damora Therapeutics, Inc. Common Stock in a research note on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective for the company. HC Wainwright started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Thursday, June 11th. They issued a “buy” rating and a $45.00 target price on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday, June 18th. Royal Bank Of Canada started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and issued a $35.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, June 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has an average rating of “Moderate Buy” and an average price target of $42.43.

Damora Therapeutics, Inc. Common Stock Stock Up 10.7%

The stock has a market capitalization of $1.85 billion, a price-to-earnings ratio of -5.37 and a beta of 1.46. The business’s 50-day moving average is $23.79 and its two-hundred day moving average is $25.45.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). As a group, analysts forecast that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth approximately $40,000. Geode Capital Management LLC purchased a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at $266,000. Virtu Financial LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter worth $49,000. Sigma Planning Corp acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $334,000. Finally, Two Sigma Investments LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter worth $76,000. Institutional investors and hedge funds own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.